Diagnostics & biomarkers

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Alzheimer’s Blood Testing Moves the Disease Clock Earlier

WHO’s New AMR Plan Makes Stewardship and Access a Single Test

Can cortisol become the next target in type 2 diabetes?

An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test

AI Pathology Starts Moving Toward Treatment Selection

Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis

Huntington’s Disease Gets an Oral Target-Engagement Signal
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
